| Qualigen Therapeutics is a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Co.'s drug compound QN-302 is being developed to target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Co.'s anticancer drug candidate, QN-247 is aptamer-based and in development to treat a variety of cancer types, including liquid and solid tumors. Co.'s RAS-F portfolio is designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS and NRAS effector pathways. We show 11 historical shares outstanding datapoints in our coverage of QLGN's shares outstanding history.|
Understanding the changing numbers of QLGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like QLGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching QLGN by allowing them to research QLGN shares outstanding history
as well as any other stock in our coverage universe.